Small molecule · Inhibitor of ubiquitin specific peptidase 1 (USP1) · developed by Tango Therapeutics
TNG348 is an orally bioavailable small molecule that allosterically binds and inhibits the deubiquitinating enzyme USP1, blocking its deubiquitinating activity. USP1 supports DNA repair through the Fanconi anemia complex and translesion synthesis, and TNG348 is being studied in breast, ovarian, pancreatic and prostate cancers, including BRCA-mutated and HRD-positive tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06065059 | Phase 1/2 | Breast Cancer | Terminated | TNGX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
BRCA-Associated Breast CarcinomaBRCA-Mutated Ovarian CarcinomaBRCA1 MutationBreast CancerHRD Positive Advanced Ovarian CancerOvarian CancerPancreas CancerProstate Cancer
Updated Nov 1, 2026. Something wrong or missing? Report it on the TNGX page.
See TNGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TNGX catalysts and pipeline →